Bioengineered Liver System Passes Safety Test in Phase I Trial
A novel extracorporeal bioengineered liver shows potential in supporting patients with acute liver failure.
1Phase I Safety Milestone
A phase I trial evaluated the miroliverELAP, a single-use bioengineered liver system designed for patients with liver failure. Christopher J. Danford of Intermountain Health reported that the system demonstrated safety during the 48-hour treatment window. No serious or unexpected adverse events directly linked to the device occurred among the seven participants.
2Innovative Biological Mechanism
The device functions by using a decellularized porcine liver scaffold seeded with allogeneic human endothelial and liver cells. These cells are derived from donated human livers deemed unsuitable for transplantation. This extracorporeal circuit replicates essential human liver functions, providing critical support for patients who currently lack viable treatment options beyond transplantation.
3Patient Cohort Characteristics
The study enrolled seven critically ill patients aged 27 to 43, primarily suffering from acute alcoholic hepatitis or acute-on-chronic liver failure. Participants had a mean MELD score of 36, indicating severe disease progression. Inclusion criteria required specific thresholds for hepatic encephalopathy and international normalized ratio levels, excluding those already eligible for transplants.
4Efficacy and Clinical Improvement
Beyond safety, the system showed early signs of efficacy during the trial. Four of the five patients who completed the full treatment experienced improvements in encephalopathy. Furthermore, all five participants either ceased vasopressor therapy or achieved a 75% reduction in their requirements by the end of the 48-hour treatment period.
5Adverse Event Profile
Researchers recorded 42 total adverse events throughout the study period. During treatment, 17 events occurred, with 11 possibly related to the system, including thrombocytopenia, anemia, and bleeding. Post-treatment, 25 events were noted, including six serious cases. Five of these serious events involved patient deaths attributed to the underlying progression of liver disease.
6Regulatory and Future Outlook
The FDA granted the miroliverELAP system Regenerative Medicine Advanced Therapy designation in April to accelerate development. Following these phase I results, the research team is preparing to initiate phase II and III clinical trials. The ultimate goal is to bridge patients to recovery or successful organ transplantation using this external support.
7Addressing Transplant Shortages
Liver failure syndromes like fulminant hepatic failure remain devastating conditions with limited therapeutic interventions. Because the demand for transplantable livers far exceeds the supply, many patients die while waiting. This bioengineered system aims to provide a temporary bridge, potentially increasing the number of patients who become eligible for life-saving transplants.
8Contextualizing Clinical Significance
While this study provides initial evidence of safety and potential efficacy, it remains the first human trial for this specific technology. The 21-day post-treatment survival data for the five patients who completed therapy offers a baseline for future research. Ongoing trials will be essential to confirm these preliminary findings in larger cohorts.
Original article: MedPage Today — Bioengineered Liver System Passes Safety Test in Phase I Trial